Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Dahlöf B, et al. Among authors: omvik p. Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3. Lancet. 2002. PMID: 11937178 Clinical Trial.
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; LIFE Study Group. Lindholm LH, et al. Among authors: omvik p. Lancet. 2002 Mar 23;359(9311):1004-10. doi: 10.1016/S0140-6736(02)08090-X. Lancet. 2002. PMID: 11937179 Clinical Trial.
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S; LIFE study group. Lindholm LH, et al. Among authors: omvik p. J Hypertens. 2002 Sep;20(9):1879-86. doi: 10.1097/00004872-200209000-00035. J Hypertens. 2002. PMID: 12195132 Clinical Trial.
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y; LIFE substudy. Ibsen H, et al. Among authors: omvik p. J Hypertens. 2004 Sep;22(9):1805-11. doi: 10.1097/00004872-200409000-00026. J Hypertens. 2004. PMID: 15311110 Clinical Trial.
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Kizer JR, Dahlöf B, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Edelman JM, Snapinn SM, Harris KE, Devereux RB. Kizer JR, et al. Among authors: omvik p. Hypertension. 2005 Jan;45(1):46-52. doi: 10.1161/01.HYP.0000151324.05355.1c. Epub 2004 Dec 6. Hypertension. 2005. PMID: 15583076 Clinical Trial.
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Ibsen H, et al. Among authors: omvik p. Hypertension. 2005 Feb;45(2):198-202. doi: 10.1161/01.HYP.0000154082.72286.2a. Epub 2005 Jan 17. Hypertension. 2005. PMID: 15655123 Clinical Trial.
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Kjeldsen SE, Lyle PA, Kizer JR, Dahlöf B, Devereux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn SM, Harris KE, Wedel H; LIFE Study Group. Kjeldsen SE, et al. Among authors: omvik p. J Clin Hypertens (Greenwich). 2005 Mar;7(3):152-8. doi: 10.1111/j.1524-6175.2005.04254.x. J Clin Hypertens (Greenwich). 2005. PMID: 15785156 Free PMC article. Clinical Trial.
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Fyhrquist F, Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H; LIFE Study Group. Fyhrquist F, et al. Among authors: omvik p. Hypertension. 2005 Apr;45(4):580-5. doi: 10.1161/01.HYP.0000161186.55933.6b. Hypertension. 2005. PMID: 15790960
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Fossum E, Moan A, Kjeldsen SE, Devereux RB, Julius S, Snapinn SM, Edelman JM, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Dahlöf B; LIFE Study Group. Fossum E, et al. Among authors: omvik p. J Am Coll Cardiol. 2005 Sep 6;46(5):770-5. doi: 10.1016/j.jacc.2005.05.060. J Am Coll Cardiol. 2005. PMID: 16139123 Free article. Clinical Trial.
151 results